Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis

Neurology

Volumn 47, Issue 6, 1996, Pages 1383-1388

  Miller, R G ^a   Moore, D ^a   Young, L A ^a   Armon, C ^b   Barohn, R J ^g   Bromberg, M B ^c,h   Bryan, W W ^g   Gelinas, D F ^a   Mendoza, M C ^a   Neville, H E ^c,d,h   Parry, G J ^f   Petajan, J H ^c,h   Ravits, J M ⁱ   Ringel, S P ^c,h   Ross, M A ^e  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES; VERTIGO;

EID: 10544254257     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1383     Document Type: Article

References (16)

1. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurology 1995;68:7-20.
2. Choi DW. Glutamate neurotoxicity and disease of the nervous system. Neuron 1988;1:623-634.
3. Taylor CP. Gabapentin - mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:829-841.
4. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-651.
5. Gurney M, Cutting FB, Zhai P, et al. Antioxidants and inhibitors of glutamatergic transmission have therapeutic benefit in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
6. Lacomblez L, Bensimon G, Leigh PN, et al. A dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347:1425-1436.
7. Ross MA, Parry GJ, Miller RG, et al. Evaluation of amyotrophic lateral sclerosis diagnostic criteria (ALSDC) for a controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) [abstract]. Neurology 1995;45(suppl 4):A280.
8. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical limits of amyotrophic lateral sclerosis workshop contributors. J Neurol Sci 1994;124:96-107.
9. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis (ALS). Ann Neurol 1996;39:256-260.
10. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1987.
11. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis (ALS). Neurology 1993; 43:1316-1322.
12. Lange DJ, Felice KJ, Gelinas DF, et al. A double-blind placebo controlled therapeutic trial to assess the efficacy of recombinant human insulin-like growth hormone (rhIGF-1) in the treatment of amyotrophic lateral sclerosis: a multicenter, double-blind, placebo-controlled clinical study. Presentation at the 6th International Symposium on ALS/MND, Dublin, Ireland, 1995.
13. Smith SA, Miller RG, Murphy JR, et al. Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 1994; 124(suppl):84-87.
14. Miller RG, Smith SA, Murphy JR, et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 1996;19:511-515.
15. Miller RG, Shepherd R, Dao H, et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Disord 1996;6:101-104.
16. Smith RA, Melmed S, Sherman B, et al. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993;16:624-633.